SCHEMBL1815819

SCHEMBL1815819

CC(CN1CCOCC1)C(=O)OCO[C]=O

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
GAA P10253 1/20 0.40
USP2 O75604 1/20 0.40
NPC1 O15118 1/20 0.39
L3MBTL1 Q9Y468 4/20 0.39
KDM4E B2RXH2 2/20 0.38
ALOX12 P18054 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ANPEP P15144 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11668730 0.80 ALDH1A1 (0.62) ALDH1A1LMNACYP3A4CYP2C19GAA
SCHEMBL14477058 0.80 ALDH1A1 (0.62) ALDH1A1LMNACYP3A4CYP2C19GAA
SCHEMBL1815820 0.79 ALDH1A1 (0.54) ALDH1A1LMNACYP3A4CYP2C19GAA
SCHEMBL1816293 0.78 ALDH1A1 (0.64) ALDH1A1LMNACYP3A4CYP2C19GAA
SCHEMBL1816291 0.76 ALDH1A1 (0.62) ALDH1A1LMNACYP3A4CYP2C19GAA
SCHEMBL22480293 0.73 ALDH1A1 (0.54) ALDH1A1LMNACYP3A4CYP2C19GAA
SCHEMBL9512804 0.73 ALDH1A1 (0.72) ALDH1A1LMNAUSP2NPC1L3MBTL1
SCHEMBL22480297 0.72 ALDH1A1 (0.53) ALDH1A1LMNACYP3A4CYP2C19GAA
SCHEMBL14276784 0.72 ALDH1A1 (0.70) ALDH1A1LMNAUSP2NPC1L3MBTL1
SCHEMBL500091 0.72 ALDH1A1 (0.96) ALDH1A1LMNAUSP2NPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130005730-A1 NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS MEDIVIR AB (SE) 2013-01-03 US disclosed
EP-2499120-A1 NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS Novadex Pharmaceuticals AB (SE) 2012-09-19 EP disclosed
WO-2011056126-A1 NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS NOVADEX PHARMACEUTICALS AB (SE) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005730-A1 NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS REN, AGTR1, ACE ALDH1A1 273/4885LMNA 2124/4885CYP3A4 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.